Skip to main content
TipRanks
Go Ultimate75% OFF

Addex Therapeutics (ADXN) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

Addex Therapeutics has a market cap or net worth of CHF 3.52M. The enterprise value is CHF 4.26M.

Market Cap
CHF 3.52M
Enterprise Value
CHF 4.26M

Share Statistics

Addex Therapeutics has 311,654,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
311,654,500
Owned by Insiders
―
Owned by Institutions
0.04%

Financial Efficiency

Addex Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -54.47%.

Return on Equity (ROE)
-1.41
Return on Assets (ROA)
-1.06
Return on Invested Capital (ROIC)
-54.47%
Return on Capital Employed (ROCE)
-0.55
Revenue Per Employee
57.67K
Profits Per Employee
-2.24M
Employee Count
3
Asset Turnover
0.03
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Addex Therapeutics is -0.59. Addex Therapeutics’s PEG ratio is -0.02.

PE Ratio
-0.59
PS Ratio
55.65
PB Ratio
2.53
Price to FCF
-1.47
Price to Operating Cash Flow
-2.02
PEG Ratio
-0.02

Income Statement

In the last 12 months, Addex Therapeutics had revenue of 173.00K and earned -6.73M in profits. Earnings per share was -0.06.

Revenue
173.00K
Gross Profit
164.39K
Operating Income
-2.81M
Pretax Income
-6.84M
Net Income
-6.73M
EBITDA
-2.81M
Earnings Per Share (EPS)
-0.06

Cash Flow

In the last 12 months, operating cash flow was -2.39M and capital expenditures -5, giving a free cash flow of -2.39M billion.

Operating Cash Flow
-2.39M
Free Cash Flow
-2.39M
Free Cash Flow per Share
-0.01

Dividends & Yields

Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-67.93%
Earnings Yield
-142.68%

Stock Price Statistics

Beta
0.72
52-Week Price Change
-52.63%
50-Day Moving Average
0.02
200-Day Moving Average
0.04
Relative Strength Index (RSI)
94.18
Average Volume (3m)
1.55M

Important Dates

Addex Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 09, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

Addex Therapeutics as a current ratio of 1.40, with Debt / Equity ratio of 0.73%

Current Ratio
1.40
Quick Ratio
1.40
Debt to Market Cap
0.00
Net Debt to EBITDA
0.57
Interest Coverage Ratio
-175.94

Taxes

In the past 12 months, Addex Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Addex Therapeutics EV to EBITDA ratio is -0.82, with an EV/FCF ratio of -1.18.

EV to Sales
44.73
EV to EBITDA
-0.82
EV to Free Cash Flow
-1.18
EV to Operating Cash Flow
-1.18

Balance Sheet

Addex Therapeutics has CHF 767.33K in cash and marketable securities with CHF 77.50K in debt, giving a net cash position of CHF 689.83K billion.

Cash & Marketable Securities
CHF 767.33K
Total Debt
CHF 77.50K
Net Cash
CHF 689.83K
Net Cash Per Share
CHF 0.00
Tangible Book Value Per Share
CHF 0.01

Margins

Gross margin is 41.19%, with operating margin of -4115.07%, and net profit margin of -10874.58%.

Gross Margin
41.19%
Operating Margin
-4115.07%
Pretax Margin
-10867.08%
Net Profit Margin
-10874.58%
EBITDA Margin
-5446.68%
EBIT Margin
-5508.56%

Analyst Forecast

The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-50.34%
EPS Growth Forecast
4.75%

Scores

Smart Score
0
AI Score
48